Tysabri Approved In EU; Biogen Will Initiate A Staggered Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec/Elan’s natalizumab is indicated for second-line use, mirroring the revised U.S. indication.
You may also be interested in...
Biogen Idec Shifts Gears On Tysabri Relaunch
“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.
Biogen Idec Shifts Gears On Tysabri Relaunch
“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.
1,000 Physicians, 4,500 Patients Enrolled In Tysabri TOUCH Program
Elan reports early data on uptake of the MS therapy, but says it is too early to tell how many enrollees will convert to patients treated.